Zura Bio (NASDAQ: ZURA) has announced the appointments of Mark Eisner, MD, PhD, and Ajay Nirula, MD, PhD, to its board of directors (BOD), effective February 21, 2026. Neil Graham, MBBS, MD, MPH, stepped down from the BOD on that date.
Dr. Eisner, is a biotechnology executive with more than 25 years of leadership in clinical development and immunology. He currently serves as EVP and CMO of Vir Biotechnology, where he oversees clinical development, regulatory sciences, and medical affairs.
Dr. Nirula is a physician-scientist and biotechnology executive with more than two decades of leadership in immunology research and clinical development. He currently serves as EVP and the head of R&D at Recludix Pharma.
In a statement, Amit Munshi, chairman of the board, commented, “Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a global scale. As we advance our Phase 2 programs and evaluate new growth opportunities, their experience will be instrumental. Their decision to join the board reflects their conviction in our strategy and pipeline.”
